Ro 20-1724
(Synonyms: 4-(3-丁氧基-4-甲氧基苯基)咪唑啶-2-酮,4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone) 目录号 : GC13842A selective PDE4 inhibitor
Cas No.:29925-17-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Ro 20-1724 is a cell-permeable, cAMP-specific phosphodiesterase type IV (PDE4) inhibitor (IC50 = 2 µM).[1],[2] It weakly inhibits PDE3 with a Ki value greater than 25 µM.1 Ro 20-1724 inhibits the release of cytokines and other inflammatory signals as well as prevents the development of reactive oxygen species.[3] It is often used to study cAMP-related functions in vascular cells.[4]
Reference:
[1]. Reeves, M.L., Leigh, B.K., and England, P.J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochemistry Journal 241, 535-541 (1987).
[2]. Soderling, S.H., Bayuga, S.J., and Beavo, J.A. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proceedings of the National Academy of Sciences of the United States of America 95, 8991-8996 (1998).
[3]. Totani, L., Piccoli, A., Dell'Elba, G., et al. Phosphodiesterases type-4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury. Arteriosclerosis, Thrombosis, and Vascular Biology 34(8), 1689-1696 (2014).
[4]. Zhai, K., Hubert, F., Nicolas, V., et al. β-Adrenergic cAMP signals are predominantly regulated by phosphodiesterase type 4 in cultured adult rat aortic smooth muscle cells. PLoS One 7(10), 1-13 (2012).
| Cas No. | 29925-17-5 | SDF | |
| 别名 | 4-(3-丁氧基-4-甲氧基苯基)咪唑啶-2-酮,4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | ||
| 化学名 | (S)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one | ||
| Canonical SMILES | O=C(NC1)N[C@H]1CC(C=C2OCCCC)=CC=C2OC | ||
| 分子式 | C15H22N2O3 | 分子量 | 278.35 |
| 溶解度 | 25 mg/mL in DMSO, 30 mg/mL in DMF, 25 mg/mL in Ethanol | 储存条件 | Store at- 20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5926 mL | 17.963 mL | 35.926 mL |
| 5 mM | 0.7185 mL | 3.5926 mL | 7.1852 mL |
| 10 mM | 0.3593 mL | 1.7963 mL | 3.5926 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。